PrimeStreet Capital Unveils 4 Megatrend Themes to Navigate Global Crisis Delivers 7x NAV-MOIC Growth and 180% IRR in 2.5 Years Signals Potential FDA Approval for ALS Drug Registration

Mr. VIRIT VICHITVADAKAN, Co-Founder and Partner of PrimeStreet Capital—one of Thailand's leading global venture capital firms under PrimeStreet Group—stated that the global economy is showing sustained signs of deceleration due to multiple factors, including trade uncertainty, global tariff increases by the U.S., inflationary pressure, and geopolitical tensions, especially in the Middle East. These risks have severely impacted energy prices and investor confidence worldwide.

"Crises often bring hidden opportunities—especially in the investment world, where downturns present chances to acquire quality assets at attractive prices," Mr. VIRIT said. "Investors need to pivot their strategies, emphasizing diversification into high-potential assets, especially those with low correlation to traditional markets—such as alternative assets including Private Equity (PE) and Venture Capital (VC), particularly within megatrend sectors."

According to 25-year historical data from Cambridge Associates, these asset classes have generated an average annual return of 23.1% with lower volatility than many traditional investments.

The Global Venture Capital Fund managed by PrimeStreet Capital, now in its third year, focuses on four primary megatrend themes:

1. Healthcare and Wellness
2. Environment and Infrastructure
3. Impact Technology
4. Food, Water, and Natural Resources

The fund has achieved over 7x growth in Net Asset Value (NAV), with an unrealized MOIC (Multiple on Invested Capital) close to 7x and an IRR of 180%—significantly outperforming the global 3-year VC IRR average of approximately 20.2%, according to Pitchbook's global performance data.

Looking ahead to the second half of 2025 and into 2026, PrimeStreet Capital remains focused on these four megatrend pillars through targeted investments in four core companies. Among them is Novel Immunologic Therapy for Neurodegenerative Diseases, a biotech firm currently in the final stages of FDA approval for a new ALS treatment. The drug has already passed initial approval phases and is undergoing final efficacy testing with over 300 patients across the U.S., Europe, and Japan.

Notably, several major Japanese pharmaceutical companies have expressed strong interest in negotiating licensing deals for the manufacturing and distribution rights of the ALS treatment—indicating strong commercial potential in the Asian market. This opportunity is expected to deliver outsized returns in a fraction of the time typically seen in the biotech sector, where development and commercialization often span over a decade.

"We aim to begin distributing returns to investors within 2-3 years and close the fund by year 5 or 6—well ahead of industry averages," said Mr.VIRIT. "Our commitment remains firm: to generate profits while delivering systemic benefits, in line with our philosophy of 'bringing global innovations home for Thailand's benefit.' We strive to collaborate with Thailand's public health sector and local businesses to uplift the nation's infrastructure in a sustainable way."

• ข่าวo:member
• ข่าวo:fin
• ข่าวo:loc
• ข่าวen